-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
MaxCyte (NASDAQ:MXCT) Stock Price Down 9.3%
MaxCyte (NASDAQ:MXCT) Stock Price Down 9.3%
MaxCyte, Inc. (NASDAQ:MXCT – Get Rating)'s stock price traded down 9.3% during trading on Friday . The stock traded as low as $5.50 and last traded at $5.56. 3,514 shares were traded during trading, a decline of 99% from the average session volume of 658,173 shares. The stock had previously closed at $6.13.
Wall Street Analysts Forecast Growth
Separately, BTIG Research increased their price objective on shares of MaxCyte from $10.00 to $11.00 and gave the company a "buy" rating in a report on Sunday, August 14th.
Get MaxCyte alerts:MaxCyte Stock Down 5.9 %
The company has a 50-day simple moving average of $5.62.
Insider Transactions at MaxCyte
In other news, major shareholder Casdin Partners Master Fund, L sold 3,235,548 shares of the firm's stock in a transaction on Friday, July 1st. The stock was sold at an average price of $4.30, for a total value of $13,912,856.40. Following the transaction, the insider now directly owns 10,735,786 shares in the company, valued at approximately $46,163,879.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.11% of the stock is owned by corporate insiders.Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in MXCT. Quantbot Technologies LP acquired a new stake in shares of MaxCyte in the 2nd quarter valued at about $27,000. Freemont Management S.A. acquired a new stake in shares of MaxCyte in the 1st quarter valued at about $68,000. Nkcfo LLC acquired a new stake in shares of MaxCyte in the 1st quarter valued at about $91,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of MaxCyte in the 2nd quarter valued at about $76,000. Finally, PDT Partners LLC acquired a new stake in shares of MaxCyte in the 2nd quarter valued at about $76,000. 66.40% of the stock is currently owned by institutional investors.
MaxCyte Company Profile
(Get Rating)
MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Featured Stories
- Get a free copy of the StockNews.com research report on MaxCyte (MXCT)
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
MaxCyte, Inc. (NASDAQ:MXCT – Get Rating)'s stock price traded down 9.3% during trading on Friday . The stock traded as low as $5.50 and last traded at $5.56. 3,514 shares were traded during trading, a decline of 99% from the average session volume of 658,173 shares. The stock had previously closed at $6.13.
纳斯达克股票代码：MXCT-GET Rating)周五交易中，Maxcell股价下跌9.3%。该股最低跌至5.5美元，最新报5.56美元。当日成交量为3,514股，较658,173股的平均成交量下降99%。此前该股收盘价为6.13美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Separately, BTIG Research increased their price objective on shares of MaxCyte from $10.00 to $11.00 and gave the company a "buy" rating in a report on Sunday, August 14th.
另外，BTIG Research在8月14日周日的一份报告中将MaxCyte的股票目标价从10.00美元上调至11.00美元，并给予该公司“买入”评级。
MaxCyte Stock Down 5.9 %
Maxcell股票下跌5.9%
The company has a 50-day simple moving average of $5.62.
该公司的50日简单移动均线切入位为5.62美元。
Insider Transactions at MaxCyte
MaxCyte的内幕交易
Institutional Inflows and Outflows
机构资金流入和流出
Several hedge funds and other institutional investors have recently added to or reduced their stakes in MXCT. Quantbot Technologies LP acquired a new stake in shares of MaxCyte in the 2nd quarter valued at about $27,000. Freemont Management S.A. acquired a new stake in shares of MaxCyte in the 1st quarter valued at about $68,000. Nkcfo LLC acquired a new stake in shares of MaxCyte in the 1st quarter valued at about $91,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of MaxCyte in the 2nd quarter valued at about $76,000. Finally, PDT Partners LLC acquired a new stake in shares of MaxCyte in the 2nd quarter valued at about $76,000. 66.40% of the stock is currently owned by institutional investors.
几家对冲基金和其他机构投资者最近增持或减持了MXCT的股份。Quantbot Technologies LP在第二季度收购了MaxCyte的新股份，价值约2.7万美元。Freemont Management S.A.在第一季度收购了MaxCyte的新股份，价值约6.8万美元。Nkcfo LLC在第一季度收购了MaxCyte的新股份，价值约91,000美元。Zurcher Kantonalbank苏黎世广东银行在第二季度收购了MaxCyte的新股，价值约7.6万美元。最后，PDT Partners LLC在第二季度收购了MaxCyte的新股份，价值约76,000美元。66.40%的股票目前由机构投资者持有。
MaxCyte Company Profile
Maxcell公司简介
(Get Rating)
(获取评级)
MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Maxcell，Inc.是一家全球生命科学公司，致力于下一代细胞疗法的发现、开发和商业化。其产品包括：Expert ATx，一种用于中小规模转基因的静态电穿孔仪器；Expert STx，一种用于蛋白质生产和药物开发的流动电穿孔设备，以及用于基于细胞分析的治疗靶点的表达；Expert GTx，一种用于治疗应用中大规模转基因的流动电穿孔设备；以及Expert VLx，用于超大规模细胞工程。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on MaxCyte (MXCT)
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 免费获取StockNews.com关于MaxCyte的研究报告(MXCT)
- 为什么特斯拉的股票保持弹性？
- 需要关注的2只半导体类股走势逆转
- 小盘股的裁员是楼市的晴雨表吗？
- 好市多盈利后价格疲软是买入的好时机吗？
- CrowdStrike是否会从增加每股收益指引中获得提振？
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
接收MaxCyte日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对MaxCyte和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧